Prognostic value of DNA and mRNA E6/E7 of human papillomavirus in the evolution of cervical intraepithelial neoplasia grade 2

Biomarker Insights

Volumn 9, Issue , 2014, Pages 15-22

  Discacciati, Michelle G ^a   da Silva, Ismael D C G ^b   Villa, Luisa L ^c   Reis, Leandro ^d   Hayashi, Priscila ^d   Costa, Maria C ^c   Rabelo Santos, Silvia H ^e   Zeferino, Luiz C ^f  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^d Department of Molecular Biology Salomão and Zoppi Laboratory ^*  (Brazil)

^e FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cervical intraepithelial neoplasia; Disease progression; E6 protein; Human papillomavirus 16; Neoplasm regression; Papillomavirus E7 proteins; Spontaneous; Viral oncogene proteins

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS IDENTIFICATION; WART VIRUS;

EID: 84898454091     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMIMI.S14296     Document Type: Article

References (27)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.
2. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89(1):101-5.
3. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26S:K1-16.
4. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15:1274-80.
5. Spinillo A, Dal Bello B, Alberizzi P, et al. Clustering patterns of human papillomavirus genotypes in multiple infections. Virus Res. 2009;142:154-9.
6. Pitta DR, Sarian LO, Campos EA, et al. Phylogenetic classification of human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia in women from a densely populated Brazilian urban region. Sao Paulo Med J. 2009;127(3):122-7.
7. Fife KH, Cramer HM, Schroeder JM, Brown DR. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol. 2001;64:550-9.
8. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32S:S7-15.
9. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17:2536-45.
10. Sotlar K, Stubner A, Diemer D, et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol. 2004;74(1):107-16.
11. Cattani P, Zannoni GF, Ricci C, et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol. 2002;47(12):3895-901.
12. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50.
13. Kraus I, Molden T, Holm R, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006;44:1310-7.
14. Wheeler CM, Hunt WC, Schiffman M, Castle PE, Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194:1291-9.
15. Cattani P, Siddu A, D'Onghia S, et al. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J Clin Microbiol. 2009;47:2136-41.
16. Varnai AD, Bollmann M, Bankfalvi A, et al. Predictive testing of early cervical by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 2008;19:457-65.
17. Sorbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One. 2011;6(10):e26022.
18. Snijders PJF, Steenbergen RDM, Heideman DAM, Meijer CJLM. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208:152-64.
19. D'Ottaviano MGL, Zeferino LC, Cecatti JG, Terrabuio DR, Martinez EZ. Prevalence of cervical intraepithelial neoplasia and invasive carcinoma based on cytological screening in the region of Campinas, São Paulo, Brazil. Cad Saude Pública. 2004;20:153-9.
20. Wright, TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson, EJ, American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340-5.
21. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-9.
22. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu. 1973;8:301-28.
23. Scully RE, Bonfiglio TA, Kurman RI, Silverberg SG, Wilkins EJ. Histological typing of female genital tract tumors. World Health Organization. International histological classification of tumors. Berlin: Springer-Verlag; 1994:36-49.
24. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
25. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials; Future II Study Group. Lancet. 2007;369:1861-8.
26. Bulkmans NW, Bleeker MC, Berkhof J, et al. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer. 2005;117:177-81.
27. Discacciati MG, de Souza CA, d'Otavianno MG, et al. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):204-8.